Atai Life Sciences N.V.
ATAI
Price:
$1.2599
Market Cap:
$211.41M
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder...[Read more]
Industry
Biotechnology
IPO Date
2021-06-18
Stock Exchange
NASDAQ
Ticker
ATAI
The ROE as of September 2024 (TTM) for Atai Life Sciences N.V. (ATAI) is -25.82%
According to Atai Life Sciences N.V.’s latest financial reports and current stock price. The company's current ROE is -25.82%. This represents a change of 178.73% compared to the average of -9.26% of the last 4 quarters.
Atai Life Sciences N.V. (ATAI) Historical ROE (quarterly & annually)
How has ATAI ROE performed in the past?
The mean historical ROE of Atai Life Sciences N.V. over the last ten years is -34.98%. The current -25.82% ROE has changed -26.18% with respect to the historical average. Over the past ten years (40 quarters), ATAI's ROE was at its highest in in the March 2020 quarter at 27.27%. The ROE was at its lowest in in the December 2020 quarter at -95.34%.
Average
-34.98%
Median
-29.75%
Minimum
-112.44%
Maximum
38.09%
Atai Life Sciences N.V. (ATAI) ROE by Quarter and Year
Discovering the peaks and valleys of Atai Life Sciences N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 277.99%
Maximum Annual ROE = 38.09%
Minimum Annual Increase = -242.38%
Minimum Annual ROE = -112.44%
| Year | ROE | Change |
|---|---|---|
| 2023 | -16.56% | -69.47% |
| 2022 | -54.23% | -242.38% |
| 2021 | 38.09% | -133.88% |
| 2020 | -112.44% | 277.99% |
Atai Life Sciences N.V. (ATAI) Average ROE
How has ATAI ROE performed in the past?
The current ROE of Atai Life Sciences N.V. (ATAI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.90%
5-year avg
-34.98%
10-year avg
-34.98%
Atai Life Sciences N.V. (ATAI) ROE vs. Peers
How is ATAI’s ROE compared to its peers?
Atai Life Sciences N.V.’s ROE is greater than Mind Medicine (MindMed) Inc. (-71.33%), greater than Seelos Therapeutics, Inc. (-13.07%), greater than GH Research PLC (-16.39%), greater than Freeline Therapeutics Holdings plc (-110.68%), greater than Cybin Inc. (-42.30%), greater than Fortress Biotech, Inc. (-226.63%), greater than Bio-Path Holdings, Inc. (-2842.40%), less than Vaccinex, Inc. (1.11%), greater than Eliem Therapeutics, Inc. (-47.03%), less than Opthea Limited (360.05%), greater than Molecular Partners AG (-33.08%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than iTeos Therapeutics, Inc. (-18.19%), less than Wesana Health Holdings Inc. (242.19%), less than BioVaxys Technology Corp. (328.15%), greater than Algernon Pharmaceuticals Inc. (-213.50%), less than AXIM Biotechnologies, Inc. (54.15%),
| Company | ROE | Market cap |
|---|---|---|
| -71.33% | $518.67M | |
| -13.07% | $1.30M | |
| -16.39% | $419.87M | |
| -110.68% | $28.28M | |
| -42.30% | $148.90M | |
| -226.63% | $45.86M | |
| -2842.40% | $2.65M | |
| 1.11% | $9.76M | |
| -47.03% | $550.56M | |
| 360.05% | $511.67M | |
| -33.08% | $172.94M | |
| -28.01% | $1.59B | |
| -18.19% | $436.07M | |
| 242.19% | $233.16K | |
| 328.15% | $9.82M | |
| -213.50% | $1.78M | |
| 54.15% | $2.14M |
Build a custom stock screener for Atai Life Sciences N.V. (ATAI) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atai Life Sciences N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Atai Life Sciences N.V. (ATAI) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Atai Life Sciences N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Atai Life Sciences N.V.'s ROE?
How is the ROE calculated for Atai Life Sciences N.V. (ATAI)?
What is the highest ROE for Atai Life Sciences N.V. (ATAI)?
What is the 3-year average ROE for Atai Life Sciences N.V. (ATAI)?
What is the 5-year average ROE for Atai Life Sciences N.V. (ATAI)?
How does the current ROE for Atai Life Sciences N.V. (ATAI) compare to its historical average?